SOUTH KOREA · OPENDART
Vaxcell-Bio Therapeutics
박셀바이오 · 323990 · KOSDAQ · Healthcare · Biotechnology
Score
Not ranked: no net buying on the exchange by an individual insider in the last 180 days.
Insiders' buying price vs the latest close
Insiders paid 7,835.00 KRW a share on average (2 purchase lines, 2 buyers, 2026-03-23 – 2026-03-23). The close on 2026-10-16 was 47.5% below that price.
Prices paid are weighted by shares and taken from the filings; dividends are not counted. Not scored.
Insider trades on the exchange
Purchases and sales on the exchange in the last 12 months. The filing gives the settlement date; the trade date is two trading days earlier.
Other changes in holdings · 5
Option exercises, grants, new shares, inheritance, gifts, off-exchange trades and trades by companies and funds. Not counted in the score.
| Date | Insider | Role | Reason | Shares | Filing |
|---|---|---|---|---|---|
| 2026-01-02 | Kim Sang Ki | Senior managing director | New registration(+) | 1,928 | DART ↗ |
| 2026-01-02 | Kim Kyung Keun | Senior managing director | New registration(+) | 1,118 | DART ↗ |
| 2026-01-02 | Suh MIn Soo | Managing director | New registration(+) | 400 | DART ↗ |
| 2025-04-08 | Lee Jeong Min | Senior managing director | Merger(+) | 192,517 | DART ↗ |
| 2024-10-18 | Lee Je-jung | CEO | 증여(-) | 150,000 | DART ↗ |